Predict your next investment

Formlabs company logo
Corporation
COMPUTER HARDWARE & SERVICES | Computer Storage & Peripherals / Printing & Imaging Equipment
formlabs.com

See what CB Insights has to offer

Founded Year

2011

Stage

Series E | Alive

Total Raised

$261.25M

Valuation

$0000 

Last Raised

$150M | 5 mos ago

About Formlabs

Formlabs designs and manufactures 3D printing systems for engineers, designers, and artists.

Formlabs Headquarter Location

35 Medford Street Suite 201

Somerville, Massachusetts, 02143,

United States

617-702-8476

Latest Formlabs News

Cellink-Organovo Lawsuit Over Bioprinting Patents is Far From Over

Sep 24, 2021

Cellink-Organovo Lawsuit Over Bioprinting Patents is Far From Over September 6, 2021 Steve Grundahl started Midwest Prototyping in the very early days of 3D printing. On this episode of the 3DPOD, he tells us about how he got financing, how he grew... September 1, 2021 A 3D printing double unicorn, Formlabs is one of the most talked about and followed startups out there. The firm pioneered desktop stereolithography and the professional desktop segment and now... August 23, 2021 Luis Baldez is Senior Manager of Market Development for HP, but he’s also the Executive Director of the 3MF Consortium. 3MF is trying to get the 3D printing industry to... Objectify 3DPOD Episode 77: Max Lobovsky, Formlabs Co-Founder & CEO 3DPOD Episode 76: 3D Printing File Formats with 3MF Executive Director Luis Baldez Search Contact us below to learn more Share this Article In the highly competitive biotechnology and pharmaceutical industries, hardware manufacturers are under a lot of pressure to provide the best, most efficient, and fastest platforms for researchers. Bioprinting , in particular, is a unique niche within the 3D printing ecosystem, where an increasing number of startups are competing to position their systems in major drug companies, specialized biotechnology firms, academic institutions, government agencies, and private and public research centers. However, as in nearly every industry, this competition will lead to lawsuits. The latest complaint filed by pioneering firm Organovo said several of the bioprinters made by biotech company Cellink infringe on patents for their technology. According to a grievance filed on July 27, 2021, in a federal court in Waco, Texas, the San Diego-based manufacturer is seeking cash compensation for the patents Cellink has allegedly infringed upon, as well as a court order blocking Cellink from using three of Organovo’s patents relating to the devices, systems, and methods of tissue fabrication ( US9149952B2 ), improvements to bioprinting technology that facilitate automation of tissue and organ fabrication processes ( US9315043B2 ), and a way for printing a 3D structure ( US9855369B2 ). Additionally, the Swedish-based business is accused of infringing on a fourth patent owned by the University of Missouri and exclusively licensed to Organovo, entitled “Self-assembling cell aggregates and methods of making engineered tissue by organ printing” ( US9752116B2 ). As reflected in Organovo’s complaint, Cellink’s Bio X is accused of infringing three patents, and the Bio X6 is accused of infringing one. Cellink, however, claims the accusations are invalid. In fact, the company had filed two petitions on June 3, 2021, for Inter Partes Review (IPR), challenging the validity of two of Organovo’s patents that relate to its current bioprinting technology before the U.S. Patent and Trademark Office (USPTO). Cellink’s Bio X and Bio X6 bioprinters. Image courtesy of Cellink. A spokesperson for Cellink told 3DPrint.com that if those IPR proceedings were granted, they could lead to the cancellation of the challenged claims in Organovo’s patents. Organovo expects the USPTO to decide by December 2021 whether to institute Cellink’s IPRs. If it does, it will then conduct an administrative trial to determine the patentability of the patent claims challenged in the IPRs and issue a final determination within a year. However, if the USPTO declines to institute an IPR to a contested claim, then the decision is final and non-appealable. Ultimately, if Cellink is successful in the IPR proceedings, Organovo may lose the IPR patents, limiting the company’s ability to stop others from using or commercializing products and technologies similar or identical to theirs. “While Cellink respects valid intellectual property, we believe that Organovo’s patent claims at issue are invalid, not infringed, or both. Cellink remains steadfastly committed to evolving the future of medicine. As the world’s leading bio convergence company, we look forward to continuing to set the trends in the bio convergence space and collaborating with our industry peers to work toward solving the major health challenges we face as a society,” claimed Cellink’s source. Also, as of June 7, 2021, Cellink filed for a declaratory judgment regarding non-infringement in the U.S. District Court in Delaware. The complaint was presented jointly with two recently acquired companies, MatTek Corporation , an in vitro technology firm founded by MIT professors in 1985, and Visikol , a spin-off startup out of Rutgers University specializing in advanced drug discovery solutions, including 3D cell culture assays. The filing explains that the dispute over intellectual property dates as far back as 2019 when the two biotech companies reportedly had a dispute over the patents. At the time, Organovo sent a letter to Cellink stating that the company had used three of its patents to market its bioprinting technology. Several discussions followed until the two parties ceased any contact in March 2021, and just a month later, Cellink initiated legal proceedings. 3DPrint.com reached out to Organovo, and the company had this to say about the lawsuit: “Organovo is built upon a respect for intellectual property rights, and early on we licensed IP from top universities and then built our own patented innovations in house. Professional IP lawyers, as third parties, have been publicly recognizing that IP portfolio as broad and foundational since as far back as 2015, before Cellink announced its first printer. Intellectual property laws exist to protect and promote innovation and they cover just this type of circumstance. In a highly irregular move, Cellink started this fight by filing against Organovo, leading Organovo to conclude that Cellink must doubt its own freedom to operate. Organovo quite simply will not be bullied by a company with little track record of innovation that now wants to sue its way to clear sailing. We are happy to teach Cellink to respect the intellectual property rights deriving from our own patents and those we license from the innovative professors who launched the field of bioprinting.” Organovo’s 3D bioprinting technology. Image courtesy of Organovo. Cellink and Organovo are two of the most renowned bioprinting companies in the industry. Recently rebranded as BICO , Cellink has been an active player since its inception in 2016 in Gothenburg, Sweden. BICO currency oversees 11 subsidiaries , including Cellink, and has a growing pipeline of upcoming acquisitions and bioconvergence technologies, not to mention dozens of partnerships with universities, public and private institutions, and researchers worldwide. As for Organovo, the startup launched in 2007, is a pioneer and was one of the big driving forces behind bioprinting technology. Developer of the first 3D bioprinted liver tissue, Organovo had the potential to revolutionize medical research, but in 2017 Organovo Founder and CEO Keith Murphy left the company, and it was all downhill from there. In August 2019, company officials halted all research and development led programs and laid off 69% of its overall workforce to extend its cash runway as it explored available “strategic alternatives to generate value from its technology platform and intellectual property.” However, by September 2020, Murphy was back as the company’s newly appointed Executive Chairman of the Board, with a renewed team ready to develop regenerative medicine therapies to treat a range of severe liver diseases, which was part of Organovo’s original vision. Inevitable or not, at some point or another, many businesses will face a legal dispute. In the world of 3D printing, several brands have undergone litigation, including Stratasys and MakerBot, Formlabs , Markforged , and many more. As for patent infringement cases, statistics reveal that between 95% and 97% of lawsuits are settled out of court. For now, Organovo and Cellink are each sure about their respective claims, and both companies are set on expanding their brand technologies, so we’ll have to follow this case as it unravels in the next two months.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Research containing Formlabs

Get data-driven expert analysis from the CB Insights Intelligence Unit.

CB Insights Intelligence Analysts have mentioned Formlabs in 5 CB Insights research briefs, most recently on Sep 30, 2021.

Expert Collections containing Formlabs

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Formlabs is included in 6 Expert Collections, including 3D Printing.

3

3D Printing

594 items

Companies working in additive manufacturing and non-traditional, customization fabrication.

S

Smart Money VCs (2017-2019)

6,297 items

We crunched the data to identify the 24 VC firms with the best combination of portfolio valuations and investment outcomes.

U

Unicorns- Billion Dollar Startups

859 items

A

Advanced Manufacturing

1,075 items

C

Consumer Hardware

2,912 items

I

Industrial 3D Printing

153 items

Formlabs Patents

Formlabs has filed 86 patents.

The 3 most popular patent topics include:

  • 3D printing
  • Manufacturing
  • 3D printing processes
patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/26/2019

9/28/2021

3D printing processes, Laser applications, 3D printing, Fused filament fabrication, Metalworking

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

2/26/2019

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

9/28/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

3D printing processes, Laser applications, 3D printing, Fused filament fabrication, Metalworking

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Formlabs Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Formlabs Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.